Literature DB >> 24577541

Enrollment in clinical cancer trials: how are we doing and what are the obstacles to improving enrollment rates? A 2-year retrospective review of pediatric cancer trial enrollment in New Zealand.

Andrew J Dodgshun1, Mandy P De Silva, Peter Bradbeer, Siobhan Cross.   

Abstract

Clinical trials contribute to the establishment of the best therapy for children with cancer. This study looks at rates of enrollment in therapeutic clinical trials over a 2-year period in New Zealand and examines the reasons for nonenrollment. All new diagnoses of cancer in children aged 16 or younger over the period of 1 January, 2009 to 31 December, 2010 were identified through the New Zealand Child Cancer Registry. Clinical trial enrollment status was identified from the medical records. For those not enrolled, the reason for nonenrollment was ascertained. A total of 28% of children diagnosed with cancer who received chemotherapy with curative intent in this time period were enrolled on clinical trials. The 2 most common reasons for nonenrollment in this study were that no study was open locally in which to enroll children (27%) or that previously open-clinical trials were closed to accrual at the time of the child's diagnosis (20%). In New Zealand, enrollment rates on clinical trials for children with cancer are lower than expected.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24577541     DOI: 10.1097/MPH.0000000000000123

Source DB:  PubMed          Journal:  J Pediatr Hematol Oncol        ISSN: 1077-4114            Impact factor:   1.289


  2 in total

1.  Most children with cancer are not enrolled on a clinical trial in Canada: a population-based study.

Authors:  Jason D Pole; Randy Barber; Rose-Émilie Bergeron; Anne Sophie Carret; David Dix; Ketan Kulkarni; Emilie Martineau; Alicia Randall; David Stammers; Caron Strahlendorf; Douglas R Strother; Tony H Truong; Lillian Sung
Journal:  BMC Cancer       Date:  2017-06-05       Impact factor: 4.430

Review 2.  Navigating the Regulatory Landscape to Develop Pediatric Oncology Drugs: Expert Opinion Recommendations.

Authors:  Elly Barry; Darrin Beaupre; Eileen Blasi; Jaimie A Walsh; Scott L Weinrich; Daniel R Arenson; Ira A Jacobs
Journal:  Paediatr Drugs       Date:  2021-06-26       Impact factor: 3.022

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.